SOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Philippe Menu Sells 5,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the company’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $7.26, for a total transaction of $36,300.00. Following the sale, the insider owned 195,993 shares of the company’s stock, valued at approximately $1,422,909.18. The trade was a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, October 5th, Philippe Menu sold 7,394 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.13, for a total value of $60,113.22.
• On Tuesday, August 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.68, for a total value of $43,400.00.
• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total value of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.66, for a total value of $28,300.00.

SOPHiA GENETICS Trading Up 3.3%

NASDAQ SOPH opened at $7.29 on Friday. The firm has a market cap of $611.59 million, a PE ratio of -6.34 and a beta of 0.95. SOPHiA GENETICS SA has a 1-year low of $3.75 and a 1-year high of $8.98. The stock has a 50-day moving average of $7.98 and a 200-day moving average of $6.24. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. As a group, sell-side analysts forecast that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Institutional Trading of SOPHiA GENETICS

Several large investors have recently modified their holdings of SOPH. AWM Investment Company Inc. bought a new stake in shares of SOPHiA GENETICS in the second quarter worth about $9,809,000. Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS during the 1st quarter valued at approximately $2,157,000. Sei Investments Co. bought a new position in SOPHiA GENETICS during the 1st quarter valued at approximately $1,772,000. Maven Securities LTD bought a new position in SOPHiA GENETICS during the 2nd quarter valued at approximately $866,000. Finally, Hennion & Walsh Asset Management Inc. bought a new position in SOPHiA GENETICS during the 2nd quarter valued at approximately $567,000. 31.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SOPH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research increased their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of SOPHiA GENETICS in a research report on Monday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.